The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis
- PMID: 25230908
- DOI: 10.1007/s11064-014-1435-7
The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis
Abstract
O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene. Epigenetic silencing of the MGMT promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma (GBM) who receive alkylating agents. But the prognostic of MGMT promoter methylation in GBM patients of different race is still ambiguous. Based on an univariate or multivariate analysis between different race (Caucasian and Asian), a meta-analysis of the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients was conducted. A total of 6,309 patients from 50 studies were involved in the analysis. Random effect models were applied to estimate the pooled hazard ratio (HR) with 95 % confidence intervals (CIs) for GBM patients of different race prognosis, the Chi square-based Q test was used to test heterogeneity. Begg's (funnel plot method) and Egger's linear regression tests were adopted to check publication bias (a bias with regard to what is likely to be published, among what is available to be published). The HR value estimated for OS was 0.524 (95 % CI 0.428-0.640) by univariate analysis and 0.427 (95 % CI 0.355-0.513) by multivariate analysis in Caucasian. The HR value estimated for OS was 0.892 (95 % CI 0.469-1.698) by univariate analysis and 0.562 (95 % CI 0.394-0.804) by multivariate analysis in Asian. The HR value estimated for PFS was 0.526 (95 % CI 0.372-0.743) by univariate analysis and 0.437 (95 % CI 0.356-0.537) by multivariate analysis in Caucasian. The HR value estimated for PFS was 0.132 (95 % CI 0.006-3.027) by multivariate analysis in Asian. This data revealed that GBM patients with MGMT promoter methylation had longer OS and PFS by univariate or multivariate analysis in Caucasian regardless of therapeutic intervention. However, GBM patients with MGMT promoter methylation only had longer OS by multivariate analysis in Asian.
Similar articles
-
The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.Fam Cancer. 2013 Sep;12(3):449-58. doi: 10.1007/s10689-013-9607-1. Fam Cancer. 2013. PMID: 23397067
-
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.J Cell Physiol. 2018 Jan;233(1):378-386. doi: 10.1002/jcp.25896. Epub 2017 May 16. J Cell Physiol. 2018. PMID: 28266716 Review.
-
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.World J Surg Oncol. 2016 Oct 12;14(1):261. doi: 10.1186/s12957-016-1012-4. World J Surg Oncol. 2016. PMID: 27733166 Free PMC article. Review.
-
MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.J Neurooncol. 2017 Jul;133(3):615-622. doi: 10.1007/s11060-017-2478-9. Epub 2017 May 23. J Neurooncol. 2017. PMID: 28536992
-
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?J Neurosurg. 2019 Mar 1;130(3):780-788. doi: 10.3171/2017.11.JNS171710. Epub 2018 May 4. J Neurosurg. 2019. PMID: 29726772
Cited by
-
Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis.Brain Tumor Res Treat. 2017 Oct;5(2):64-69. doi: 10.14791/btrt.2017.5.2.64. Epub 2017 Oct 31. Brain Tumor Res Treat. 2017. PMID: 29188206 Free PMC article.
-
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.Medicine (Baltimore). 2017 Jul;96(27):e7422. doi: 10.1097/MD.0000000000007422. Medicine (Baltimore). 2017. PMID: 28682902 Free PMC article.
-
Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.Cancer Manag Res. 2017 Sep 20;9:411-425. doi: 10.2147/CMAR.S140447. eCollection 2017. Cancer Manag Res. 2017. PMID: 29033608 Free PMC article. Review.
-
A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.World Neurosurg. 2016 Apr;88:260-269. doi: 10.1016/j.wneu.2015.12.081. Epub 2015 Dec 31. World Neurosurg. 2016. PMID: 26746331 Free PMC article.
-
MGMT promoter methylation in Peruvian patients with glioblastoma.Ecancermedicalscience. 2018 Feb 14;12:812. doi: 10.3332/ecancer.2018.812. eCollection 2018. Ecancermedicalscience. 2018. PMID: 29515653 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials